These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 20546257

  • 1. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [Abstract] [Full Text] [Related]

  • 2. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M.
    BMC Nephrol; 2014 Nov 18; 15():180. PubMed ID: 25407798
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy of an intestine-specific inhibitor of microsomal triglyceride transfer protein and peroxisome proliferator-activated receptor γ agonist in diabetic rat.
    Sakata S, Mera Y, Kuroki Y, Nashida R, Kakutani M, Ohta T.
    J Diabetes Res; 2014 Nov 18; 2014():890639. PubMed ID: 24772450
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan 18; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 9. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
    Pickavance LC, Brand CL, Wassermann K, Wilding JP.
    Br J Pharmacol; 2005 Feb 18; 144(3):308-16. PubMed ID: 15655531
    [Abstract] [Full Text] [Related]

  • 10. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
    van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.
    Circulation; 2009 Apr 21; 119(15):2069-77. PubMed ID: 19349323
    [Abstract] [Full Text] [Related]

  • 11. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G, Maffioli P.
    Curr Mol Pharmacol; 2012 Jun 21; 5(2):272-81. PubMed ID: 22122457
    [Abstract] [Full Text] [Related]

  • 12. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.
    Hsieh MC, Lin KD, Tien KJ, Tu ST, Hsiao JY, Chang SJ, Lin SR, Shing SJ, Chen HC.
    Metabolism; 2010 Aug 21; 59(8):1139-44. PubMed ID: 20045142
    [Abstract] [Full Text] [Related]

  • 13. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.
    J Clin Endocrinol Metab; 2008 Jan 21; 93(1):118-24. PubMed ID: 17956948
    [Abstract] [Full Text] [Related]

  • 14. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
    Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M.
    Lancet; 2009 Jul 11; 374(9684):126-35. PubMed ID: 19515415
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
    Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J.
    J Am Coll Cardiol; 2008 Sep 02; 52(10):869-81. PubMed ID: 18755353
    [Abstract] [Full Text] [Related]

  • 17. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A.
    Cardiovasc Diabetol; 2019 Jun 17; 18(1):80. PubMed ID: 31208414
    [Abstract] [Full Text] [Related]

  • 18. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.
    Diabetes Care; 2006 May 17; 29(5):1016-23. PubMed ID: 16644631
    [Abstract] [Full Text] [Related]

  • 19. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.
    Diabetes; 2003 Jun 17; 52(6):1364-70. PubMed ID: 12765945
    [Abstract] [Full Text] [Related]

  • 20. KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
    Konda VR, Desai A, Darland G, Grayson N, Bland JS.
    PLoS One; 2014 Jun 17; 9(1):e87848. PubMed ID: 24498211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.